Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Neoplasms Clinical Trial

Official title:

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03564691
• Other study ID #: 4830-001
• Secondary ID: MK-4830-0012019-
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: July 11, 2018
• Est. completion date: September 28, 2025

Study information

• Verified date: May 2024
• Source: Merck Sharp & Dohme LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study consists of several parts: dose escalation, dose expansion, dose expansion in Chinese participants residing in China, and coformulation. Dose escalation is to evaluate the safety, tolerability, and preliminary efficacy of MK-4830 monotherapy administration (Arms A and B) and in combination with pembrolizumab (Arm C). Dose expansion is to evaluate the objective response rate (ORR) of MK-4830 in combination with pembrolizumab (Arms A-F); evaluate the safety and tolerability of MK-4830 administered in combination with pembrolizumab, carboplatin, and pemetrexed (Arm G) and of MK-4830 administered in combination with pembrolizumab and lenvatinib (Arm H); evaluate the safety, tolerability and ORR of MK-4830 in combination with pembrolizumab plus chemotherapy (Arms I-L); and evaluate the safety and tolerability of MK-4830 in combination with pembrolizumab in Chinese participants from China (Arm M). The coformulation part (Arm N) evaluates the safety and tolerability of MK-4830A (coformulation of MK-4830 800 mg + pembrolizumab 200 mg). There is no formal hypothesis testing in this study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 442
• Est. completion date: September 28, 2025
• Est. primary completion date: September 28, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Dose escalation participants: Has any histologically- or cytologically-confirmed advanced/metastatic solid tumor by pathology report and has received, has been intolerant to, or has been ineligible for all treatment known to confer clinical benefit. Solid tumors of any type are eligible for enrollment

• Has measurable disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1), Response Assessment in Neuro-Oncology (RANO), or modified RECIST (mRECIST) as assessed by the local site investigator/radiology

• Submits an evaluable baseline tumor sample for analysis (either a recent or archival tumor sample). This inclusion criterion does not apply to Expansion phase Arm M

• Dose Escalation Part C and Back-fill participants: Has 1 or more discrete malignant lesions that are amenable to biopsy

• Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. This inclusion criterion does not apply to Expansion phase Arm B

• Demonstrates adequate organ function

• A male participant must agree to use an approved contraception(s) during the treatment period and for at least 180 days after the last dose of study treatment and refrain from donating sperm during this period

• A female participant is eligible to participate if she is not pregnant, not breastfeeding, and either not a woman of childbearing potential (WOCBP) OR if a WOCBP agrees to follow the study contraceptive guidance during the treatment period and for at least 180 days after the last dose of study treatment

• Expansion phase Arm A participants:

• Has histologically or cytologically confirmed metastatic pancreatic adenocarcinoma

• Received at least 1 prior line of therapy and no more than 3 prior lines of systemic therapy

• Expansion phase Arm B participants:

• Has histologically or cytologically confirmed unresectable glioblastoma multiforme (GBM) or its variants

• Has a Karnofsky performance status (KPS) = 70

• Has had no more than 1 prior line of therapy for GBM. Radiation with or without chemotherapy is acceptable as the prior treatment

• Has shown unequivocal evidence for tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan by contrast within 2 weeks prior to randomization

• Has an interval of at least 3 weeks (to randomization) between prior surgical resection (one week for stereotactic biopsy)

• Has an interval of at least 12 weeks from the completion of radiation therapy to randomization unless there is unequivocal histologic confirmation of tumor progression or radiographic progression outside of the prior radiation field

• Is neurologically stable (eg, without a progression of neurologic symptoms or requiring escalating doses of systemic steroid therapy within last 2 weeks) and clinically stable

• Expansion phase Arm C participants:

• Has histologically confirmed recurrent or metastatic head and neck squamous cell cancer (HNSCC) of the oral cavity, oropharynx, hypopharynx, and/or larynx that is considered incurable by local therapies

• Has experienced disease progression at any time during or after treatment with a platinum-containing (eg, carboplatin or cisplatin) regimen with or without cetuximab

• Expansion phase Arm D participants:

• Has histologically confirmed advanced or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx, and/or larynx that is considered incurable by local therapies

• Has not had any prior programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) therapy

• Expansion phase Arms E and F participants:

• Has a histologically or cytologically confirmed diagnosis of advanced (Stage IIIb) or Stage IV metastatic non-small-cell lung cancer (NSCLC)

• Has received no prior systemic therapy for chemotherapy or other targeted or biological antineoplastic therapy treatment for Stage IIIb or Stage IV metastatic NSCLC. Treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed if therapy was completed at least 6 months prior to the diagnosis of advanced disease. Participants with prior treatment with an anti-PD-1 or PD-L1 agent are not eligible

• Expansion phase Arm G participants:

• Has a histologically or cytologically confirmed diagnosis of advanced (Stage IIIb) or Stage IV metastatic nonsquamous NSCLC (American Joint Committee on Cancer (AJCC) version 8)

• Is able to tolerate chemotherapy with carboplatin and pemetrexed

• Has received no prior systemic therapy for advanced NSCLC

• Expansion phase Arm H participants:

• Has histologically confirmed diagnosis of renal cell cancer (RCC) with clear cell component with or without sarcomatoid features

• Has locally advanced/metastatic disease or has recurrent disease

• May have received 1 or 2 prior lines of systemic therapy for advanced RCC

• Expansion phase Arm I participants:

• Has histologically confirmed diagnosis of recurrent and/or metastatic gastric or gastroesophageal junction adenocarcinoma that is considered incurable by local therapies

• Has received and progressed on at least two prior chemotherapy regimens

• If tumor was if human epidermal growth factor receptor 2 (HER2/neu) positive, participant must have previously received treatment with trastuzumab

• Expansion phase Arm J participants

• Has histologically confirmed high-grade epithelial ovarian, fallopian tube or primary peritoneal carcinoma

• Has received 1 or 2 prior lines of systemic therapy, including at least 1 prior platinum-based therapy

• Has radiographic evidence of disease progression

• Is a candidate for paclitaxel chemotherapy

• Expansion phase Arm K participants:

• Has locally recurrent inoperable breast cancer OR have metastatic breast cancer not previously treated

• Has confirmed triple-negative breast cancer (TNBC)

• Has completed treatment for Stage I-III breast cancer, if indicated, and =6 months elapsed between the completion of treatment and first documented local or distant disease recurrence

• Has been treated with (neo)adjuvant anthracycline

• Expansion phase Arm L participants:

• Has histologically confirmed diagnosis of recurrent and/or advanced mesothelioma that is considered incurable by standard therapies

• Is eligible to receive standard chemotherapy

• Expansion phase Arm M participants

• Has any histologically or cytologically confirmed advanced/metastatic solid tumor by pathology report and have received, been intolerant of, been ineligible for, or refused all treatment known to confer clinical benefit

• Has received up to 2 prior systemic regimens for the treatment of advanced/metastatic solid tumor

• Is a Chinese participant residing in China

• Coformulation Arm N participants

• Has any histologically- or cytologically-confirmed advanced/metastatic solid tumor by pathology report and have received, been intolerant to, been ineligible for, or refused all treatment known to confer clinical benefit

Exclusion Criteria:

• Has had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) prior to the first dose of study therapy, or has not recovered from any adverse events (AEs) that were due to cancer therapeutics administered more than 4 weeks earlier

• Has not recovered from all radiation-related toxicities to Grade 1 or less, requires corticosteroids, and had radiation pneumonitis

• Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years

• Has known untreated central nervous system metastases or known carcinomatous meningitis. This exclusion criterion does not apply to Expansion phase Arm B

• Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related AEs

• Has previously had a severe hypersensitivity reaction to treatment with a monoclonal antibody or has a known sensitivity to any component of pembrolizumab and/or chemotherapy agents

• Has an active infection requiring therapy

• Has a history or current interstitial lung disease

• Has a history of noninfectious pneumonitis that required steroids or current pneumonitis

• Has an active autoimmune disease that has required systemic treatment in the past 2 years except vitiligo or resolved childhood asthma/atopy

• Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, or New York Heart Association Class III or IV congestive heart failure

• Has a known history of human immunodeficiency virus (HIV)

• Has a known active hepatitis B or C

• Is taking chronic systemic steroids in doses >10 mg daily of prednisone or equivalent within 7 days prior to the first dose of trial treatment

• Has not fully recovered from any effects of major surgery without significant detectable infection. Surgical proceduress that required general anesthesia must be completed at least 2 weeks before first study treatment administration. Surgery requiring regional/epidural anesthesia must be completed at least 72 hours before first study treatment administration and participants should be recovered

• Has received a live or live-attenuated virus vaccine within 30 days prior to first dose of study intervention

• Is currently participating and receiving study therapy in a study of an investigational agent or has participated and received study therapy in a study of an investigational agent or has used an investigational device within 28 days of administration of MK-4830

• All Expansion phase participants:

• Tumor types with known MSI-high status are not eligible

• Expansion phase Arm A participants:

• Has received more than 3 lines of prior therapy for advanced disease (pancreatic cancer)

• Expansion phase Arm B participants:

• Has tumor primarily localized to the brainstem or spinal cord

• Has presence of diffuse leptomeningeal disease or extracranial disease

• Has recurrent tumor greater than 6 cm in maximum diameter

• Requires treatment with moderate or high dose systemic corticosteroids for at least 3 days within 2 weeks of randomization

• Expansion phase Arm D participants:

• Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy treatment for their advanced metastatic HNSCC

• Expansion phase Arm E and F participants:

• Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy treatment for their Stage IIIb or Stage IV metastatic NSCLC

• Has had prior treatment with any anti-PD-1, PD-L1, or programmed cell death-ligand 2 (PD-L2) agent

• Expansion phase Arm G participants:

• Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy treatment for their Stage IIIb or Stage IV nonsquamous NSCLC

• Has had prior treatment with any anti-PD-1, PD-L1, or PD-L2 agent

• Expansion phase Arm H participants:

• Has a clinically significant gastrointestinal (GI) abnormality

• Has a history of untreated deep vein thrombosis or pulmonary embolism within 6 months prior to screening

• Has poorly controlled hypertension

• Has active GI bleeding

• Has evidence of inadequate wound healing

• Has active bleeding disorder or other history of significant bleeding episodes within 30 days prior to randomization

• Has hemoptysis within 6 weeks prior to randomization

• Has radiographic evidence of encasement or invasion of a major blood vessel, or of intratumoral cavitation

• Expansion phase Arm I participants:

• Has experienced weight loss > 10 % over 2 months prior to first dose of study therapy

• Has clinical evidence of ascites

• Has peritoneal metastases

• Expansion phase Arm J participants:

• Has non-epithelial cancers, including borderline, malignant Müllerian mixed mucinous, malignant Brenner's tumor and undifferentiated carcinoma and/or germ cell tumors and/or sex cord - stromal tumors

• Has received more than 2 prior lines of systemic therapy for ovarian cancer

• Expansion phase Arm K participants:

• Has a known history of hypersensitivity or allergy to the study chemotherapies and/or any of their components

• Expansion phase Arm L participants:

• Has a known history of hypersensitivity or allergy to the study chemotherapies and/or any of their components

• Is receiving any medication prohibited in combination with study chemotherapies as described in the respective product labels, unless medication was stopped within 7 days prior to randomization

• All Participants (Arms A through N)

• Has symptomatic pleural effusion (eg, cough, dyspnea, pleuritic chest pain)

• Has had an allogenic tissue/solid organ transplant.

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• MK-4830
MK-4830 will be administered intravenously (IV) Q3W. In Part C, MK-4830 will be administered after completion of pembrolizumab infusion. Dose escalation will proceed based on emerging safety and tolerability data of MK-4830 as monotherapy (Part A and B) and as combination therapy with pembrolizumab (Part C). For each dose level, an assessment will be made of the safety and tolerability data in order to define the next dose level to be tested.
• Pembrolizumab
Pembrolizumab will be administered at 200 mg IV Q3W.
• Carboplatin
Carboplatin will be administered IV Q3W.
• Pemetrexed
Pemetrexed will be administered IV Q3W.
• Lenvatinib
Lenvatinib will be administered orally once daily.
• Paclitaxel
Paclitaxel will be administered IV QW on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity (Arm J) and on Days 1, 8, and 15 Q4W until disease progression or prohibitive toxicity (Arm K).
• Cisplatin
Cisplatin will be administered IV Q3W.

Biological:
• MK-4830A
MK-4830A, a coformulation of MK-4830 800 mg + pembrolizumab 200 mg, will be administered IV Q3W.

Locations

Country	Name	City	State
Australia	Princess Alexandra Hospital ( Site 0253)	Brisbane	Queensland
Australia	Liverpool Hospital-Medical Oncology ( Site 0250)	Liverpool	New South Wales
Canada	Juravinski Cancer Centre ( Site 0034)	Hamilton	Ontario
Canada	The Ottawa Hospital ( Site 0031)	Ottawa	Ontario
Canada	Princess Margaret Cancer Centre ( Site 0033)	Toronto	Ontario
China	The First Hospital of Jilin University ( Site 0803)	Changchun	Jilin
China	West China Hospital of Sichuan University ( Site 0804)	Chengdu	Sichuan
China	Shanghai Chest Hospital-Oncology department ( Site 0801)	Shanghai	Shanghai
France	Centre Oscar Lambret ( Site 2002)	Lille	Nord
France	Hôpital Européen Georges Pompidou ( Site 2003)	Paris	Ile-de-France
France	Centre Hospitalier Universitaire de Poitiers ( Site 2000)	Poitiers	Vienne
Greece	University General Hospital of Heraklion ( Site 0110)	Heraklion	Irakleio
Greece	Euromedica General Clinic of Thessaloniki-Oncology Unit ( Site 0112)	Thessaloniki
Greece	European Interbalkan Medical Center ( Site 0111)	Thessaloniki
Israel	Rambam Health Care Campus-Oncology Division ( Site 0042)	Haifa
Israel	Rabin Medical Center ( Site 0043)	Petah Tikva
Israel	Chaim Sheba Medical Center. ( Site 0044)	Ramat Gan
Israel	Sourasky Medical Center ( Site 0041)	Tel Aviv
Japan	National Cancer Center Hospital East ( Site 0400)	Kashiwa	Chiba
Japan	Japanese Foundation for Cancer Research ( Site 0401)	Tokyo
Korea, Republic of	Severance Hospital Yonsei University Health System ( Site 0300)	Seoul
Poland	Uniwersyteckie Centrum Kliniczne ( Site 0151)	Gdansk	Pomorskie
Poland	Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (	Warszawa	Mazowieckie
South Africa	Cancercare Rondebosch Oncology ( Site 0210)	Cape Town	Western Cape
South Africa	The Oncology Centre ( Site 0212)	Durban	Kwazulu-Natal
South Africa	Wits Clinical Research ( Site 0213)	Johannesburg	Gauteng
Spain	Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 0101)	Hospitalet de Llobregat	Barcelona
Spain	Centro Integral Oncologico Clara Campal START Madrid ( Site 0102)	Madrid
United States	Ohio State University Arthur G James Cancer Hospital & Richard J Solove Research Institute ( Site 00	Columbus	Ohio
United States	Henry Ford Health System ( Site 0002)	Detroit	Michigan
United States	John Theurer Cancer Center at Hackensack University Medical Center ( Site 0005)	Hackensack	New Jersey
United States	Laura and Isaac Perlmutter Cancer Center ( Site 0008)	New York	New York
United States	Washington University ( Site 0003)	Saint Louis	Missouri
United States	Utah Cancer Specialists ( Site 0011)	Salt Lake City	Utah
United States	South Texas Accelerated Research Therapeutics, LLC (START) ( Site 0001)	San Antonio	Texas
United States	University of California at San Francisco ( Site 0004)	San Francisco	California
United States	Seattle Cancer Care Alliance ( Site 0010)	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Australia,  Canada,  China,  France,  Greece,  Israel,  Japan,  Korea, Republic of,  Poland,  South Africa,  Spain, 

References & Publications (1)

Siu LL, Wang D, Hilton J, Geva R, Rasco D, Perets R, Abraham AK, Wilson DC, Markensohn JF, Lunceford J, Suttner L, Siddiqi S, Altura RA, Maurice-Dror C. First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD- — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-Limiting Toxicities (DLTs)	The occurrence of the following toxicities, if assessed by the investigator to be possibly, probably, or definitely related to study treatment administration: Grade 4 nonhematologic toxicity (not laboratory); Grade 4 hematologic toxicity lasting >=7 days, except thrombocytopenia: Any nonhematologic AE >=Grade 3 in severity, with exceptions; Any Grade 3 or Grade 4 alanine aminotransferase, aspartate aminotransferase, and/or bilirubin laboratory value; Any other nonhematologic laboratory value if: Clinically significant medical intervention is required to treat the participant, OR The abnormality leads to hospitalization, OR The abnormality persists for >1 week, OR The abnormality results in a drug-induced liver injury; Febrile neutropenia Grade 3 or Grade 4; Prolonged delay (>2 weeks) in initiating Cycle 2 due to treatment-related toxicity.; Any treatment-related toxicity that causes the participant to discontinue treatment during Cycle 1.; Grade 5 toxicity	Cycle 1 (Up to 21 days)
Primary	Number of Participants Who Experienced an Adverse Event (AE)	An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants who experienced an AE will be presented.	Up to approximately 27 months
Primary	Number of Participants Who Discontinued Study Treatment Due to an AE	An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants who discontinued study treatment due to an AE will be presented.	Up to approximately 24 months
Primary	Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or Response Assessment in Neuro-Oncology (RANO) as Assessed by Investigator	For Arms A, C-F, I, and K ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. For Arm B, ORR is defined as the percentage of participants who experience a PR or CR per RANO, determined by: disappearance or size reduction of lesions, and review of abnormalities on fluid-attenuated inversion recovery (T2/FLAIR) images; Clinical status based on age-adjusted performance; And whether daily steroid dose has changed since previous visit. The percentage of participants who experience a CR or PR based on modified RECIST 1.1 as assessed by investigator or based on RANO will be presented.	Up to approximately 24 months
Primary	ORR per Modified RECIST (mRECIST) 1.1 as Assessed by Investigator	Per protocol, ORR per mRECIST 1.1 will be reported for Arm L participants. ORR is defined as percentage of participants who have CR (disappearance of all pleural & non-pleural disease) or PR (summed measurement (SM) decrease by at least 30% from baseline scan SM) per mRECIST 1.1. The percentage of participants who experience CR or PR based on mRECIST 1.1 as assessed by investigator will be presented.	Up to approximately 24 months
Secondary	Area Under the Curve (AUC) of Plasma MK-4830	Pharmacokinetic (PK) parameter: area under the drug concentration/time curve. Samples will be drawn 24 hours pre-MK-4830 infusion and end of infusion on Day 1 of Cycles 1, 2, 4, 6, and 8, and every 4 cycles thereafter (plus cycle 3 for Dose Expansion Arms) and 2 hours post-infusion on Day 1 of Cycles 1, 2, 4, 6, and 8 (plus cycle 3 for Dose Expansion Arms); on Days 8 and 15 for cycle 1, and additionally in cycles 2-3 for Dose Escalation Arms only; and at time of drug Discontinuation and 30 days after last dose (Up to approximately 25 months). Dose Expansion Arm C additionally requires the above pre-, post-, and 2 hour post-dose samples on Day 3 of Cycle 1. Each cycle is 21 days.	At designated time points detailed in Description (Up to approximately 25 months)
Secondary	Minimum Concentration Between Doses (Ctrough) of Plasma MK-4830	PK parameter: minimum drug concentration between doses. Samples will be drawn 24 hours pre-MK-4830 infusion and end of infusion on Day 1 of Cycles 1, 2, 4, 6, and 8, and every 4 cycles thereafter (plus cycle 3 for Dose Expansion Arms) and 2 hours post-infusion on Day 1 of Cycles 1, 2, 4, 6, and 8 (plus cycle 3 for Dose Expansion Arms); on Days 8 and 15 for cycle 1, and additionally in cycles 2-3 for Dose Escalation Arms only; and at time of drug Discontinuation and 30 days after last dose (Up to approximately 25 months). Dose Expansion Arm C additionally requires the above pre-, post-, and 2 hour post-dose samples on Day 3 of Cycle 1. Each cycle is 21 days.	At designated time points detailed in Description (Up to approximately 25 months)
Secondary	Maximum Drug Concentration (Cmax) of Plasma MK-4830	PK parameter: maximum drug concentration. Samples will be drawn 24 hours pre-MK-4830 infusion and end of infusion on Day 1 of Cycles 1, 2, 4, 6, and 8, and every 4 cycles thereafter (plus cycle 3 for Dose Expansion Arms) and 2 hours post-infusion on Day 1 of Cycles 1, 2, 4, 6, and 8 (plus cycle 3 for Dose Expansion Arms); on Days 8 and 15 for cycle 1, and additionally in cycles 2-3 for Dose Escalation Arms only; and at time of drug Discontinuation and 30 days after last dose (Up to approximately 25 months). Dose Expansion Arm C additionally requires the above pre-, post-, and 2 hour post-dose samples on Day 3 of Cycle 1. Each cycle is 21 days.	At designated time points detailed in Description (Up to approximately 25 months)
Secondary	Number of Participants Positive for Anti-Drug Antibodies (ADA) After MK-4830 plus Pembrolizumab Treatment	Serum samples from participants treated with MK-4830 plus pembrolizumab will be analyzed for ADA using a neutralizing antibody assay. The number of participants positive for ADA will be reported.	At designated time points (Up to approximately 25 months)
Secondary	Minimum Concentration Between Doses (Ctrough) of Plasma Pembrolizumab in Arm M	PK parameter: minimum drug concentration between doses. Samples will be drawn 24 hours pre-pembrolizumab infusion on Day 1 of Cycles 1-4, 6, 8, and every 4 cycles thereafter; post-infusion on Day 1 of Cycle 1; and at time of drug Discontinuation and 30 days after last dose (Up to approximately 25 months). Each cycle is 21 days.	At designated time points detailed in Description (Up to approximately 25 months)
Secondary	Maximum Drug Concentration (Cmax) of Plasma Pembrolizumab in Arm M	PK parameter: maximum drug concentration. Samples will be drawn 24 hours pre-pembrolizumab infusion on Day 1 of Cycles 1-4, 6, 8, and every 4 cycles thereafter; post-infusion on Day 1 of Cycle 1; and at time of drug Discontinuation and 30 days after last dose (Up to approximately 25 months). Each cycle is 21 days.	At designated time points detailed in Description (Up to approximately 25 months)

External Links

•   Merck Clinical Trials Information
•   Plain Language Summary